High Expression of F11R/JAM‐A is Predominant in Triple‐negative Breast Cancer Subtype and Correlates with Poor Prognosis in Breast Cancer Patients

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Chih-Yeu Fang ◽  
Chi-Long Chen ◽  
Michael Hsiao
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
High Expression ◽  
Breast Cancer Patients ◽  
Cancer Subtype

scholarly journals High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Huikun Zhang ◽  
Yawen Zhao ◽  
Xiaoli Liu ◽  
Li Fu ◽  
Feng Gu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
High Expression ◽  
Breast Cancer Patients ◽  
The Relationship ◽  
Triple Negative Subtype

BackgroundBreast cancer is the most commonly diagnosed cancer worldwide. However, the well-known biomarkers are not enough to meet the needs of precision medicine. Novel targets are desirable and highly valuable for improved patient survival. In this regard, we identified complement component C7 as one of the candidates based on data from the OCOMINE database.MethodsC7 expression was examined by immunohistochemistry in 331 cases of invasive ductal carcinoma (IDC), 45 cases of ductal carcinoma in situ (DCIS), and 52 cases of non-neoplastic tissues adjacent to tumor. Then, C7 expression was further confirmed by Western blot analysis based on IDC specimens and non-neoplastic breast specimens. The relationship between the C7 expression and prognosis of breast cancer patients was analyzed in order to investigate the function of C7 in breast cancer patients. Meanwhile, we also analyzed the relationship between the C7 expression and prognosis of 149 patients treated with conventional TE (taxane and anthracycline)-based chemotherapy. Then, a cohort of patients (22 cases) treated with TE neoadjuvant chemotherapy was used to further confirm the relationship between the C7 expression and TE-based chemosensitivity.ResultsIn our present study, we reported for the first time that C7 was an independent prognostic factor of breast cancer and C7 expression of IDC tissues was higher than non-neoplastic tissues adjacent to tumor and DCIS. In a cohort of 331 IDC patients, high expression of C7 indicated poor prognosis especially in the triple negative subtype and luminal B subtype. Furthermore, C7 was also a promoting factor for triple negative subtype patients to develop bone metastasis. Meanwhile, we provided the first evidence that patients with high C7 expression were insensitive to TE (taxane and anthracycline)-based chemotherapy by analyzing a cohort of 149 patients treated with TE-based chemotherapy and another cohort of 22 patients treated with TE neoadjuvant chemotherapy.ConclusionsIn summary, high expression of C7 may promote breast cancer development and might be insensitive to TE-based chemotherapy. Our present study laid a foundation to help clinicians improve the identification of patients for TE-based chemotherapy by C7 in the era of precision medicine.

scholarly journals The expression of NEDD9 and E-cadherin correlates with metastasis and poor prognosis in triple-negative breast cancer patients

2016 ◽  
Vol Volume 9 ◽  
pp. 5751-5759 ◽  
Author(s):  
Peng Li ◽  
Tingting Sun ◽  
Qingzhong Yuan ◽  
Guozheng Pan ◽  
Jian Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Breast Cancer Patients ◽  
E Cadherin

The correlation between ERRα expression level and pathological grade, overall survival and cancer types: a study from a cohort of 150 patients with breast cancer

2021 ◽  
Vol 16 ◽  
Author(s):  
Ning Sun ◽  
Chenchen Li ◽  
Yue Teng ◽  
Yuxia Deng ◽  
Lin Shi
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Clinical Stage ◽  
High Expression ◽  
Pathological Grade ◽  
Breast Cancer Patients ◽  
Cancer Tissues

Background: Breast cancer is a common malignant tumor, threatening the general health of women worldwide. Estrogen-related receptor alpha (ERRα) is a member of nuclear receptor family and has been shown to involve in the pathophysiology of breast cancer. However, the specific relationship between ERRα and the triple negative breast cancer (TNBC), is not clear yet. Objective: This study examined the relevance between ERRα expression and different clinical features of breast cancer patients. Methods: The expression level of ERRα in 150 human breast cancer tissues (which contains 48 human triple negative breast cancer tissues) and 53 human benign breast tumor tissues using immunohistochemical staining. Results: ERRα protein level was significantly higher in breast cancer tissues than that in benign tumors. High expression of ERRα was significantly associated with the high grade but not the clinical stage and human epidermal growth factor receptor 2 of the breast cancer tissues. Its high expression was also positively correlated with triple negative breast cancer in pathological grade 2 and 3, but not in grade 1. high expression of ERRα was positively correlated with triple negative breast cancer in each clinical stage. In addition, high expression of ERRα was associated with shorter overall survival of breast cancer patients. Conclusion: In conclusion, highly expressed ERRα was associated with higher pathological grades triple-negative breast cancer and shorter overall survival. Future studies were required to recruit more patients to consolidate the current findings.

scholarly journals Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e6501 ◽  
Author(s):  
Suvimol Niyomnaitham ◽  
Napa Parinyanitikul ◽  
Ekkapong Roothumnong ◽  
Worapoj Jinda ◽  
Norasate Samarnthai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Gene Mutations ◽  
Genomic Analysis ◽  
Breast Cancer Patients ◽  
Illumina Hiseq ◽  
Hormonal Receptors

Background Triple negative breast cancer (TNBC) is a breast cancer subtype characterized by absence of both hormonal receptors and human epithelial growth factor receptor 2 (HER2). TNBC accounts for 15–20% of breast cancer. TNBC is associated with more aggressive disease and worse clinical outcome. Though the underlying mechanism of TNBC is currently unclear, the heterogeneity of clinical characteristics in various population may relate to the difference in tumor mutational profile. There were studies on TNBC gene mutations in various ethnic groups but the tumor genome data on Thai TNBC patients is currently unknown. This study aims to investigate mutational profile of Thai TNBC. Methods The patients were Thai individuals who were diagnosed with primary breast carcinoma between 2014 and 2017. All surgically removed primary tumor tissues were carefully examined by pathologists and archived as formalin-fixed paraffin-embedded tumor. TNBC was defined by absence of hormonal receptors and HER2 by immunohistochemistry. Genomic DNA was extracted, enriched and sequenced of all exomes on the Illumina HiSeq. Genomic data were then processed through bioinformatics platform to identify genomic alterations and tumor mutational burden. Results A total of 116 TNBC patients were recruited. Genomic analysis of TNBC samples identified 81,460 variants, of which 5,906 variants were in cancer-associated genes. The result showed that Thai TNBC has higher tumor mutation burden than previously reported data. The most frequently mutated cancer-associated gene was TP53 similar to other TNBC cohorts. Meanwhile KMT2C was found to be more commonly mutated in Thai TNBC than previous studies. Mutational profile of Thai TNBC patients also revealed difference in many frequently mutated genes when compared to other Western TNBC cohorts. Conclusion This result supported that TNBC breast cancer patients from various ethnic background showed diverse genome alteration pattern. Although TP53 is the most commonly mutated gene across all cohorts, Thai TNBC showed different gene mutation frequencies, especially in KMT2C. In particular, the cancer gene mutations are more prevalent in Thai TNBC patients. This result provides important insight on diverse underlying genetic and epigenetic mechanisms of TNBC that could translate to a new treatment strategy for patients with this disease.

Sign in / Sign up

Export Citation Format

Share Document